SecBot Intelligence Feed

Barclays double-upgraded Tesla from Equal-Weight to Overweight on October 26, 2026, raising its price target 21.6% to $450 from $370. The call is a significant contrarian move: Barclays has a 53% accuracy rate on 8,251 scored calls with a 3.8% average return, placing it below the top-tier firms…

Meta is offering 250 million Series A Depositary Shares (each representing a 1/20th interest in a share of Series A Mandatory Convertible Preferred Stock) at $50 per depositary share, for total gross proceeds of $12.5 billion. Concurrently, Meta expects to enter into forward sale agreements for…

Meta Platforms is conducting a $22.5 billion forward-sale equity offering of Class A common stock (expandable to $25.875 billion with the underwriters' option), using forward sale agreements with Morgan Stanley and Goldman Sachs. The company will not receive proceeds at closing; instead, it…

AITX disclosed four internal breakeven milestones in a press release, with the first (monthly operating cash breakeven) targeted for January 2027, pushed back from December 2026. The company reported Q2 FY2026 revenue of $1,985,604 (up 5% YoY) and a 54% reported gross margin, while its cash…

An institutional cluster in ARM reveals a strong bearish tilt: 4 asset managers reduced positions by $44.8M (net) while only 1 added a modest $151K. The largest seller, Robeco, executed a near-exit (-87.5% of shares, $31.9M sold), and Concurrent Investment Advisors trimmed 74.2% ($8.6M). The lone buyer, Wealth Enhancement Advisory Services, added a small position (+$151K). This suggests a coordinated de-risking by active managers, likely in response to ARM's elevated valuation or sector headwinds.

Six active asset managers accumulated $1.76B in META during Q3 2026, with Parnassus Investments, Ninety One UK, and Wealth Enhancement Advisory Services leading the buying. The cluster follows Meta's Q3 earnings report showing 26% revenue growth to $64.6B, though GAAP EPS was depressed by a $9.89B litigation charge. The institutional buying signals conviction in Meta's core business momentum despite the one-time legal charge.

Institutional activity in AMD during Q3 2026 shows a mixed picture: three smaller active managers added $69.4M in positions, while two larger asset managers trimmed a combined $557.6M. The net selling is dominated by Parnassus Investments, which cut nearly $468M, suggesting a significant conviction reduction by a major holder. The buying side is relatively small in dollar terms and includes a Canadian broker and a risk-management firm, which may reflect tactical rebalancing rather than a strong bullish thesis.

Tesla reported Q3 2026 results with total revenue roughly flat YoY at $28.0B, GAAP net income of $0.8B ($0.22 diluted EPS) declining from $1.4B ($0.39) in Q3 2025, and GAAP operating income of $0.7B declining from $1.6B. Total vehicle deliveries fell 2% YoY to 486,532 units. Operating expenses rose sharply to $4.8B, driven by SI and R&D spending. The company launched Cybercab Robotaxi service in Austin and began volume production of Tesla Semi and Optimus robots.

8 institutional buyers accumulated $6.6M in new SMCI positions during Q3 2026, while 1 seller trimmed $37.3M. The cluster is overwhelmingly bullish in count but the single large seller (Assenagon) dominates the dollar flow. This buying likely reflects anticipation of the massive Q1 FY2027 revenue pre-announcement ($18.5B-$19.5B vs prior guidance of $14.5B-$15.5B) filed one day after quarter-end, but the 45-day reporting lag means positions may have already been adjusted.

Institutional activity in MRVL during Q3 2026 was mixed: four asset managers added positions totaling $24.7M in new buying, while two sellers reduced holdings by $229.3M, led by a massive $227.2M trim from Assenagon Asset Management. The net selling pressure of ~$205M suggests institutional caution despite selective accumulation by smaller managers.

AITX reported Q2 FY2027 revenue of $1,985,604, up 5% YoY and 8% sequentially, driven by a 61% YoY increase in revenue excluding its largest customer. The company expanded its cost reduction program, targeting monthly operating cash breakeven in January 2027. However, the company remains unprofitable with a net loss and a non-cash inventory write-down, and its penny stock status and going concern risk persist.

Three active asset managers accumulated $154.1M in new PLTR positions during Q3 2026, while two trimmed $28.5M. The buying was concentrated in mid-sized additions and a doubling by Td Waterhouse Canada, but the sellers reduced larger positions.

Four Palantir insiders, including C-suite executive Taylor Ryan D., sold a total of $5.30M in shares over a one-week window. The sales are open-market and not flagged as 10b5-1 plan transactions, representing approximately 0.16% of the company's market cap — a modest but notable cluster. No insider buying offsets the selling, suggesting a cautious internal view near current price levels.

Three UiPath insiders, including CEO Daniel Dines, sold a combined $17.58M in open-market sales over a one-week window. The CEO's $16.81M sale dominates the cluster, representing roughly 0.5% of market cap. While insider sales are often liquidity-driven, the CEO's large open-market sale outside a clear 10b5-1 pattern is a notable bearish signal, especially given the company's recent history of negative stock performance.

A bearish institutional cluster formed in UiPath (PATH) during Q3 2026, with three asset managers reducing positions by a net $5.4M while only one tiny buyer (Td Waterhouse Canada) added a negligible $15K. The most aggressive seller, Assenagon Asset Management, cut its stake by 89.1%, exiting nearly all of its $6.0M position. This concentrated selling by active managers suggests a shared negative thesis on UiPath's growth trajectory or competitive positioning.

Recursion Pharmaceuticals is offering 61,540,000 shares of Class A common stock at $3.25 per share, raising approximately $187.2 million in net proceeds. The offering is priced at a 13.1% discount to the last closing price of $3.74 and represents significant dilution of ~11.5% to existing shareholders. Proceeds will fund clinical programs including a registrational study for REC-4881 in FAP and dose expansion for REC-1245, as well as platform advancement and runway extension into 2029.

Artificial Intelligence Technology Solutions Inc. (AITX) filed a Form NT 10-Q on October 15, 2026, notifying the SEC that it cannot timely file its quarterly report for the period ended August 31, 2026. The company cites delays in acquiring required information and expects to file within the 5-day grace period. This is a repeat late filing following a prior NT 10-K for the fiscal year ended February 28, 2026, indicating chronic accounting or operational delays.

Three institutional buyers accumulated $166.4M in net new TSLA positions during Q3 2026, led by Assenagon Asset Management adding $93M and Congress Asset Management nearly doubling a tiny prior stake into a $73.2M position. The cluster follows Tesla's preliminary Q3 delivery beat (486K vehicles vs ~464K produced) and precedes the full Q3 earnings release on October 21, suggesting institutions positioned ahead of the print. However, 13F data is 45+ days stale and the cluster is small (3 funds, no sellers) — the signal is modest.

Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/share, alongside positive clinical data updates (REC-4881 FAP data showing 47% median polyp reduction, REC-1245 partial responses in endometrial cancer) and a Sanofi milestone ($10M payment for optioned immunology development candidate). The offering extends cash runway into 2029 but causes ~12% dilution from the ~532M pre-offering share base. The prior quarter (Q2 2026) showed revenue of $7.7M (down 60% YoY from $19.2M) and a net loss of $131M (EPS -$0.25 vs consensus -$0.23, a miss).

Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program collaboration, triggering a $10 million milestone payment. This brings total upfront and milestone payments from Sanofi to $144 million, with over $300 million in additional milestones possible. The candidate, a potential first-in-class oral small molecule for inflammatory disease, will enter Phase 1 in 2027 with Sanofi funding development. The news is positive for the collaboration's progress but is tempered by the concurrent $200 million equity offering that dilutes existing shareholders.

Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, diluting existing shareholders by approximately 23% based on pre-offering shares outstanding. The offering, which closed the next day, extends cash runway into 2029 but represents a significant near-term dilution event.

Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data updates for REC-4881 in FAP and REC-1245 in solid tumors, plus a $10 million milestone from Sanofi for optioning a development candidate. The capital raise extends cash runway into 2029 but dilutes existing shareholders, while the clinical data and partnership milestone provide validation of the platform.

Recursion Pharmaceuticals is filing a preliminary prospectus supplement for a $200 million underwritten public offering of Class A common stock. The filing also discloses positive clinical data for REC-4881 in FAP and initial data for REC-1245, and a $10 million milestone payment from Sanofi for optioning a development candidate. The offering will dilute existing shareholders and extends cash runway into 2029.

Three Palantir insiders, including a senior executive and two directors, sold a total of $4.83M in open-market sales over a one-week period. The sales are modest relative to the company's market cap and may reflect routine portfolio diversification, but the concentration of selling by multiple insiders warrants attention.

CEO Thomas Siebel sold $5.15M worth of C3.ai shares in an open-market sale, and CFO Hitesh Lath sold $247K, totaling $5.39M in insider selling within a week. This represents approximately 1.65% of the company's $326M market cap, a significant cluster of open-market sales by top executives. The selling is material in size and seniority, signaling potential bearish conviction ahead of upcoming events.

Two Palantir insiders sold a total of $3.87M in stock over a one-week window, including a $3.62M sale by a named executive (Taylor Ryan D.) and a $254K sale by a director. The sales are open-market transactions without any indicated 10b5-1 plan, representing approximately 0.1% of Palantir's market cap. While the dollar amount is modest relative to the company's size, the absence of a plan and the involvement of a senior executive warrant attention.

Two UiPath executives (COO and CPO/CTO) sold a combined $1.27M in open-market sales over a one-week period in early October 2026. The sales are modest relative to the company's market cap (approximately 0.1%), and while they are not plan-driven, they lack the materiality to signal a strong bearish read. The cluster is notable but not alarming.

In Q2 2026, 68 institutional buyers accumulated $9.12B in META while 43 sellers reduced by $1.43B, resulting in a net inflow of $7.69B. The buying was led by mega-passive Capital Group ($4.64B increase) and active quants (RenTech, D.E. Shaw, Viking), while quant sellers (Millennium, Point72, Bridgewater) trimmed positions. The net direction is mixed — large passive accumulation contrasts with notable quant profit-taking.

A mixed institutional cluster in UiPath (PATH) for Q2 2026 shows $122.3M in net buying from 41 funds, led by new/aggressive positions from RenTech ($38.6M new) and D.E. Shaw ($38.3M added), while 28 sellers reduced by $92.4M, led by Jane Street (-$55.5M) and Point72 (-$17.6M). The divergence between quant buyers and quant sellers suggests no consensus thesis, and the 45-day reporting lag limits current relevance.

A mixed institutional cluster for Palantir (PLTR) in Q2 2026: 77 buyers accumulated $1.57B in net new positions, while 47 sellers reduced holdings by $440.6M. The buying was dominated by mega-passive funds (JPMorgan, Goldman Sachs, UBS) and two quant/asset managers (Millennium, Susquehanna) that more than quadrupled their stakes, but notable active sellers like T. Rowe Price, Capital Group, and two quant funds (Bridgewater, Point72) exited or trimmed significantly. The net $1.13B inflow is large in absolute terms but heavily passive, and the 45-day reporting lag means positions may have already been adjusted.

Goldman Sachs upgraded Palantir Technologies Inc. (PLTR) from Neutral to Buy on October 8, 2026, setting a price target of $230, implying 21.4% upside from the current price of $189.40. The firm has a 60% accuracy rate on 5 calls for PLTR with an average return of 49.3%, placing it above average among covering analysts. Consensus on PLTR is heavily bullish: 28 of 39 analysts rate it Buy (72%), 9 Hold (23%), and 2 Sell (5%). The mean price target is $195.57, median $205.05, with a high of $255 and low of $80; Goldman's $230 target sits above both the mean and median. In the past 30 days, there has been 1 upgrade and 0 downgrades, while EPS estimates for the current quarter have seen 22 upward revisions and 0 downward revisions over 30 days. Insider selling has been notable, with multiple sales by EVP Moore Alexander D. totaling over $1.9 million in September, though these may be routine. Institutional activity is mixed: JPMorgan added 36.8% and Goldman Sachs Group added 29.5%, while Capital Research trimmed 30.3% and T. Rowe Price trimmed 40.2%. Short interest stands at 56.0% of float, indicating elevated bearish positioning. The next earnings report is due November 2, 2026, within 30 days, adding a timing catalyst. Overall, the upgrade from a high-return firm with strong upward estimate momentum and heavy short interest creates a potentially explosive setup.

Meta's COO and CPO sold a combined $14.07M in open-market transactions on September 21, 2026. The CPO's sale of $14.01M dominates the cluster, representing a material insider disposition at current elevated price levels.

Seaport Global initiated coverage on Marvell Technology (MRVL) with a Buy rating and a $270 price target, representing a modest 2.9% upside from the current price of $262.36. The firm has a 52% accuracy rate on 258 calls and an average return of 2%, placing it near the middle of the analyst pack covering MRVL. The broader consensus is heavily bullish, with 43 of 50 analysts rating the stock Buy or Strong Buy, 7 at Hold, and none at Sell. The mean price target is $289.56, implying 10.4% upside, with a high of $400 and a low of $210. Recent analyst activity has been positive, with 2 upgrades and 0 downgrades in the past 30 days, and EPS estimates have been revised upward 32 times in the last month versus just 1 downward revision. Insider selling has been notable, with multiple executives including the CEO and CFO selling shares worth over $1.6 million each in recent months, creating a divergence with the bullish analyst sentiment. Institutional flows show significant accumulation, with T. Rowe Price doubling its position and Geode Capital adding 67.9%, partially offsetting the insider sales signal. The initiation adds another Buy rating to an already crowded bullish consensus, but Seaport's average accuracy and the stock's proximity to its target limit the incremental impact.

Three NVDA insiders sold a total of ~$7.38M in open-market sales over a 5-day window, including the CFO and General Counsel. Director Mark Stevens also sold ~$300M in two trades on 9/18, making this a massive cluster of insider selling. While some sales may be routine diversification, the size and breadth (CFO, GC, Director) warrant attention.

Stifel double-upgraded Microsoft Corp (MSFT) from Hold to Buy on September 23, 2026, raising its price target to $575 from $530, implying 15.5% upside from the current $498. The upgrade is a significant shift from Stifel's prior Hold stance, which it maintained as recently as September 4. Stifel has a 63% accuracy rate on 8 calls with a 5.7% average return, placing it in the top tier among firms covering MSFT. Consensus is overwhelmingly bullish: 64 of 69 analysts rate MSFT Buy or Strong Buy, with only 5 at Hold and none at Sell. The mean price target of $576.40 is nearly identical to Stifel's new $575 target, making this call closely aligned with consensus. EPS estimates have been revised upward over the past 30 days (21 up vs 8 down for the current fiscal year), and the next earnings report is due October 28, about five weeks away. Insider selling by EVP Hood Amy totaling ~$16.3M on September 14 provides a modest contra-signal, though such sales are often liquidity-driven. The bottom line: a high-conviction double upgrade from a top-tier firm that reinforces the already bullish consensus, with upward EPS revisions adding fundamental support.

Two C-suite insiders at UiPath (COO and CPO/CTO) sold a combined $2.19M in open-market sales over a one-week window. The total value is approximately 0.67% of the company's $326M market cap, which is a modest but notable insider selling cluster. The sales are not plan-driven (no 10b5-1 indication) and involve senior executives, making this a bearish signal for the stock.

Four top executives at SoundHound AI (CEO, COO, CPO, CSO) sold a combined $1.81M in open-market shares on September 15, 2026, at ~$6.33/share. A director also sold a trivial $9K on September 17. The cluster is entirely open-market selling by the C-suite, with no 10b5-1 plan indicated, and represents ~0.56% of the company's market cap — a modest but notable signal of insider conviction at current prices.

Recursion Pharmaceuticals amended its Master Agreement with Tempus AI, extending the term from five to six years and eliminating Recursion's right to terminate for convenience. Annual license fees were reduced from $42M to $14M for years 3-5, with at least $4M payable in cash. Separately, Recursion granted Tempus a non-exclusive license to its TxFM RNA model for oncology use for a $12M fee, providing a new revenue stream.

CEO Thomas Siebel and CFO Hitesh Lath sold a combined $1.93M in open-market shares over a 7-day window, with Siebel's sales totaling $5.02M when including earlier trades. The CEO's sales are tied to derivative exercises at $3.90/share, locking in a ~$3.3M profit, while the CFO's sale is a routine liquidity event at ~$221K. The total open-market sales represent ~0.3% of the company's market cap, a modest but notable insider outflow concentrated at the C-suite level.

Two C-suite insiders at SoundHound AI sold a combined $695K in open-market sales on September 15, 2026, with no indication of 10b5-1 plans. The sales represent ~0.21% of the company's $326M market cap, a modest but notable cluster from the Chief Product Officer and Chief Operating Officer.

Upstart Holdings saw a mixed insider cluster with CEO Paul Gu buying $1.28M in open-market shares on Sept 10, while President Sanjay Datta sold $3.17M on Sept 8 after exercising options. The CEO's purchase is a strong bullish signal, but the President's larger sale creates a conflicting read, though the sale is partially liquidity-driven from option exercises.

Piper Sandler initiates coverage on Marvell Technology (MRVL) with an Overweight rating and a $270 price target, implying 14.9% upside from the current $235.01. The firm has a 54% accuracy rate on 3,744 scored calls with an average return of 3.6%, placing it in the average-performing tier among covering firms. Consensus on MRVL is heavily bullish: 43 of 50 analysts rate it Buy (86%), 7 Hold (14%), and none Sell. The mean price target is $285, with a high of $400 and a low of $143. Piper Sandler's $270 target sits 5.3% below the consensus mean, reflecting a slightly more cautious stance than the Street average. Over the past 30 days, 28 EPS revisions have been upward for the next fiscal year, and 27 for the next quarter, with zero downward revisions — a strong positive momentum signal. Insider selling has been persistent, with five C-suite sales totaling ~$9M in the last two months, while congressional buys and institutional adds provide a mixed cross-platform picture. The bottom line: Piper Sandler's initiation adds a new bullish voice to an already crowded buy-side consensus, but the below-consensus target and insider selling warrant caution for active traders.

Piper Sandler initiated coverage on Broadcom Inc. (AVGO) at Overweight with a $460 price target, representing 26.2% upside from the current $364.38 close. The firm's 54% accuracy on 3,744 calls and average 3.6% return per rating places it in the middle tier among covering analysts. Consensus is overwhelmingly bullish: 52 of 57 analysts rate Buy or Strong Buy, only 5 Hold, zero Sell. The mean price target of $533.41 implies 46.4% upside, with a high of $715 and low of $215.88. Piper Sandler's $460 target sits 13.8% below the consensus mean, a relatively conservative entry point. Recent analyst momentum is positive — 3 upgrades, 0 downgrades in the past 30 days, with Macquarie upgrading to Outperform on Sept 3. EPS revisions for the current fiscal year show 2 upward revisions vs 1 downward in the past 30 days, though next-quarter estimates have been trimmed slightly. Insider selling by CFO Brazeal Mark David totaling ~$29M in late June/early July creates a mild headwind, but congressional buys from Reps. Taylor and Allen signal political insider confidence. The initiation from a mid-accuracy firm with a below-consensus target is a modestly bullish signal, not a game-changer.

Piper Sandler initiated coverage on NVDA with an Overweight rating and a $300 price target, implying 34.1% upside from the current $223.67. The firm's 86% accuracy on 7 NVDA calls and 20.3% average return place it among the top-tier covering analysts. Consensus is overwhelmingly bullish with 65 of 69 analysts at Buy/Strong Buy, a mean target of $327.65, and a high of $515. EPS revisions are strongly positive — 39 upward revisions in the past 30 days for the +1y period with zero downgrades. Insider activity shows significant selling by director Mark Stevens totaling ~$190M over Sept 3-4, a potential cautionary signal against the bullish initiation. Institutional flows are mixed: Allianz added 25.6% and Van Eck added 34.7%, while Citadel trimmed 36.7%. Short interest is elevated at 44.4% of float, suggesting heavy bearish positioning that could fuel a squeeze if the stock rallies. The initiation from a high-accuracy firm adds conviction to the already bullish consensus, but the insider selling and high short interest warrant a measured stance.

Two SMCI insiders — Director/10% owner Sara Liu and CEO Charles Liang — sold a combined $3.12M in open-market sales on September 3, 2026, at ~$36.60/share. A follow-on sale by Liu of 100,000 shares at $40 on September 4 adds another $4M, bringing the cluster total to ~$7.12M. These are material open-market sales by the CEO and a 10% owner, representing ~0.2% of SMCI's market cap, and are not plan-driven, signaling potential caution ahead of upcoming financial disclosures.

SoundHound AI completed its acquisition of LivePerson, retiring LivePerson's outstanding debt and creating a debt-free combined entity with 25 Fortune 100 customers and over 750 patents. The company also appointed John Collins, former LivePerson CFO, as its new CFO. The deal positions SoundHound to target more than $500M in future revenue from the existing customer base, but the acquisition value was not disclosed.